By jurisdiction

Australia (TGA)

Every compound we track that has a recorded status under Australia (TGA). Tap a name for the full picture, including the U.S. status and primary sources.

Australia (TGA): status by compound
CompoundStatus hereNote
BPC-157RestrictedReported as Schedule 4 (prescription-only) under the Poisons Standard.
CJC-1295RestrictedReported as Schedule 4 (prescription-only) under the Poisons Standard.
IpamorelinRestrictedReported as Schedule 4 (prescription-only) under the Poisons Standard.
Melanotan IIRestrictedSchedule 4 (prescription-only); no products registered on the ARTG; TGA has issued infringement notices for unlawful supply.
NAD+RestrictedPer a TGA safety alert, NAD/NAD+/NADH are not permitted ingredients in listed medicines.
Semaglutide (compounded)RestrictedGLP-1 analogues removed from the pharmacist compounding exemption effective Oct 1, 2024; remains Schedule 4.
SermorelinRestrictedPrescription-only (Schedule 4) as a GHRH analog; obtainable via compounding pharmacy on prescription.
TB-500 (Thymosin Beta-4)RestrictedThymosin beta-4 treated as Schedule 4 (prescription-only) under the Poisons Standard.
Thymosin Alpha-1RestrictedRegulated as Schedule 4 (prescription-only); the TGA has enforced against unlawful advertising.
Tirzepatide (compounded)RestrictedGLP-1 compounding prohibited since Oct 1, 2024; remains Schedule 4.
GHK-CuUnscheduledNot individually named in the Poisons Standard; topical cosmetic products are freely available.
SelankUnscheduledNot individually named or scheduled in the Poisons Standard.
SemaxUnscheduledNot individually named in the Poisons Standard; sits in a grey area.